ZOMEDICA CORP. |
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.141 USD | -0.42% |
|
+8.38% | -29.57% |
| Apr. 01 | Zomedica Corp. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
| Apr. 01 | Zomedica Seeks Acquisitions | CI |
Valuation
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Capitalization 1 | 120 | 35.76 | 130.1 | 300.3 | 159.7 | 196.2 |
| Enterprise Value (EV) 1 | 116.8 | 34.22 | 69.95 | 106.8 | 46.38 | 108.4 |
| P/E ratio | -6.83 x | -1.74 x | -4.61 x | -5.81 x | -9.39 x | -5.68 x |
| Yield | - | - | - | - | - | - |
| Capitalization / Revenue | - | - | - | 72,666,048 x | 8,438,024 x | 7,789,483 x |
| EV / Revenue | - | - | - | 25,831,410 x | 2,449,963 x | 4,304,730 x |
| EV / EBITDA | -7.13 x | -1.75 x | -4.25 x | -5.28 x | -2.59 x | -4.29 x |
| EV / FCF | -29.2 x | -3.87 x | -7.17 x | -16.3 x | -10.9 x | -4.75 x |
| FCF Yield | -3.42% | -25.8% | -14% | -6.15% | -9.2% | -21% |
| Price to Book | 32.8 x | -3.62 x | 2.9 x | 1.11 x | 0.6 x | 0.82 x |
| Nbr of stocks (in thousands) | 97,572 | 108,038 | 564,051 | 979,895 | 979,950 | 979,950 |
| Reference price 2 | 1.230 | 0.3310 | 0.2306 | 0.3065 | 0.1630 | 0.2002 |
| Announcement Date | 2/26/19 | 2/26/20 | 2/26/21 | 3/1/22 | 3/15/23 | 4/1/24 |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net sales | - | - | - | 4.133 | 18.93 | 25.19 |
| EBITDA 1 | -16.37 | -19.51 | -16.46 | -20.23 | -17.88 | -25.29 |
| EBIT 1 | -16.58 | -19.78 | -16.76 | -21.37 | -21.92 | -31.59 |
| Operating Margin | - | - | - | -517.14% | -115.81% | -125.43% |
| Earnings before Tax (EBT) 1 | -16.65 | -19.78 | -16.91 | -20.72 | -19.38 | -35.86 |
| Net income 1 | -16.65 | -19.78 | -16.91 | -18.38 | -17.02 | -34.53 |
| Net margin | - | - | - | -444.78% | -89.88% | -137.1% |
| EPS 2 | -0.1800 | -0.1900 | -0.0500 | -0.0527 | -0.0174 | -0.0352 |
| Free Cash Flow 1 | -3.996 | -8.833 | -9.759 | -6.562 | -4.268 | -22.81 |
| FCF margin | - | - | - | -158.77% | -22.55% | -90.58% |
| FCF Conversion (EBITDA) | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - |
| Announcement Date | 2/26/19 | 2/26/20 | 2/26/21 | 3/1/22 | 3/15/23 | 4/1/24 |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2022 Q3 | 2023 Q3 |
|---|---|---|
| Net sales | - | - |
| EBITDA | - | - |
| EBIT | - | - |
| Operating Margin | - | - |
| Earnings before Tax (EBT) | - | - |
| Net income 1 | -4.995 | -0.491 |
| Net margin | - | - |
| EPS 2 | -0.005000 | -0.001000 |
| Dividend per Share | - | - |
| Announcement Date | 11/14/22 | 11/13/23 |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | - |
| Net Cash position 1 | 3.2 | 1.54 | 60.1 | 194 | 113 | 87.8 |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - |
| Free Cash Flow 1 | -4 | -8.83 | -9.76 | -6.56 | -4.27 | -22.8 |
| ROE (net income / shareholders' equity) | -414% | -688% | -51.9% | -11% | -6.32% | -13.6% |
| ROA (Net income/ Total Assets) | -184% | -242% | -29.8% | -7.71% | -4.89% | -7.41% |
| Assets 1 | 9.037 | 8.173 | 56.75 | 238.4 | 347.7 | 465.9 |
| Book Value Per Share 2 | 0.0400 | -0.0900 | 0.0800 | 0.2800 | 0.2700 | 0.2400 |
| Cash Flow per Share 2 | 0.0200 | 0 | 0.1000 | 0.2000 | 0.0300 | 0.0100 |
| Capex 1 | 0.63 | 0.16 | 0.01 | 0.15 | 2.55 | 11.3 |
| Capex / Sales | - | - | - | 3.56% | 13.48% | 45.02% |
| Announcement Date | 2/26/19 | 2/26/20 | 2/26/21 | 3/1/22 | 3/15/23 | 4/1/24 |
1USD in Million2USD
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Annual profits - Rate of surprise
- Stock Market
- Equities
- ZOM Stock
- Financials Zomedica Corp.
